Addex Therapeutics Announces Cancellation of Epilepsy Program Following Phase II Study Results
Monday, 22 July 2024, 10:24
Overview of Addex Therapeutics' Setback
Addex Therapeutics recently announced the cancellation of its epilepsy program due to disappointing outcomes from a Phase II study.
Phase II Study Results
- The study involved the drug candidate ADX71149 (also known as JNJ-40411813).
- End of April saw the objectives not being met, leading to program cessation.
Impact of the Cancellation
- This decision may significantly impact the future of Addex Therapeutics.
- Investors should stay informed about subsequent developments.
In conclusion, while the cancellation may pose challenges, ongoing market analysis will be crucial for understanding its implications.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.